Filters

C Benson, J White, J De Bono, A O'Donnell, F Raynaud, C Cruickshank, H McGrath, M Walton, P Workman, S Kaye, J Cassidy, A Gianella-Borradori, I Judson, C Twelves

British journal of cancer 2007;96(1):29-37

Free Full Text

Abstract

Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.

Radek Jorda, Libor Havlícek, Iain W McNae, Malcolm D Walkinshaw, Jirí Voller, Antonín Sturc, Jana Navrátilová, Marek Kuzma, Martin Mistrík, Jirí Bártek, Miroslav Strnad, Vladimír Krystof

Journal of medicinal chemistry 2011;54(8):2980-93

Full Text

Abstract

Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.

Józefa Wesierska-Gadek, Matthias P Kramer

Annals of the New York Academy of Sciences 2009;1171():257-63

Full Text

Abstract

DrugScoreRNA--knowledge-based scoring function to predict RNA-ligand interactions.

Holger Gohlke, Patrick Pfeffer

Journal of chemical information and modeling 2007;47(5):1868-76

Full Text

Abstract

Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.

Wen-Son Hsieh, Ross Soo, Bee-Keow Peh, Thomas Loh, Difeng Dong, Donny Soh, Lim-Soon Wong, Simon Green, Judy Chiao, Chun-Ying Cui, Yoke-Fong Lai, Soo-Chin Lee, Benjamin Mow, Richie Soong, Manuel Salto-Tellez, Boon-Cher Goh

Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(4):1435-42

Free Full Text

Abstract

The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.

Anne Jämsä, Kristina Hasslund, Richard F Cowburn, Anders Bäckström, Mervi Vasänge

Biochemical and biophysical research communications 2004;319(3):993-1000

Full Text

Abstract

Results: 1 – 13 / 13

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Roscovitine""[mesh_terms]

Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells.

Tumor-Directed Therapeutic Targets in Cushing Disease.

Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells.

Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism.

Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels.

Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent.

Roscovitine modulates DNA repair and senescence: implications for combination chemotherapy.

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.

Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.

Monitoring of long-term effects of resveratrol on cell cycle progression of human HeLa cells after administration of a single dose.

DrugScoreRNA--knowledge-based scoring function to predict RNA-ligand interactions.

Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer.

The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.

Results for
""Roscovitine""[mesh_terms]